JAHA:术前NT-proBNP预测隔膜肌切除术后中期结局

2019-02-14 xing.T 网络

由此可见,术前NT-proBNP水平的增加是接受隔膜切除术的患者中期死亡率的较强预测因子。

脑钠尿肽前体N末端(NT-proBNP)对接受隔膜切除术的肥厚型心肌病患者的预后价值尚未得到很好的研究。

近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员回顾性地评估了2011年3月至2018年4月在研究者所在医疗中心接受隔膜切除术的758例患者(46.1±13.8岁;中位随访936天)的NT-proBNP水平。

中位NT-proBNP水平为1450.5(四分位数范围682.6-2649.5)pg/mL。总体而言,22例(2.9%)患者在随访期间死亡;其中,86.4%的患者是因血管疾病而死亡。NT-proBNP三分位数个体无全因死亡的3年生存率分别为95.2%(95%CI为91.1%至97.4%; NT-proBNP>2080 pg/mL)、98.3%(95%CI为94.6%至99.5%; NT-proBNP为947-2080pg/mL)和99.2%(95%CI为94.4%至99.9%; NT-proBNP<947pg/mL)。无心血管死亡的3年生存率分别在最高NT-proBNP三分位数个体为95.2%,中等三分位数个体为98.8%,最低三分位数个体为99.2%。Cox回归分析表明Ln(NT-proBNP)是全因死亡(风险比为2.380,95%CI为1.356-4.178,P=0.003)和心血管死亡(风险比为2.788,95%CI为1.450-5.362,P=0.002)的独立预测因子。此外,因冠状动脉疾病而进行冠状动脉旁路移植术也是此类患者心血管死亡的独立预测因子(风险比为5.178,95%CI为1.597-16.789,P=0.006)。

由此可见,术前NT-proBNP水平的增加是接受隔膜切除术的患者中期死亡率的较强预测因子。

原始出处:

Changpeng Song.et al.Preoperative NT‐proBNP Predicts Midterm Outcome After Septal Myectomy.JAHA.2019.https://www.ahajournals.org/doi/full/10.1161/JAHA.118.011075

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082941, encodeId=5b5a20829416d, content=<a href='/topic/show?id=b77b9858050' target=_blank style='color:#2F92EE;'>#隔膜肌切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98580, encryptionId=b77b9858050, topicName=隔膜肌切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Dec 19 04:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877120, encodeId=ba7318e7120a4, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 19 13:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268056, encodeId=6c6912680565e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289321, encodeId=d1e4128932170, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290350, encodeId=fecd12903504b, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602121, encodeId=47b2160212112, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082941, encodeId=5b5a20829416d, content=<a href='/topic/show?id=b77b9858050' target=_blank style='color:#2F92EE;'>#隔膜肌切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98580, encryptionId=b77b9858050, topicName=隔膜肌切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Dec 19 04:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877120, encodeId=ba7318e7120a4, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 19 13:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268056, encodeId=6c6912680565e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289321, encodeId=d1e4128932170, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290350, encodeId=fecd12903504b, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602121, encodeId=47b2160212112, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2082941, encodeId=5b5a20829416d, content=<a href='/topic/show?id=b77b9858050' target=_blank style='color:#2F92EE;'>#隔膜肌切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98580, encryptionId=b77b9858050, topicName=隔膜肌切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Dec 19 04:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877120, encodeId=ba7318e7120a4, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 19 13:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268056, encodeId=6c6912680565e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289321, encodeId=d1e4128932170, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290350, encodeId=fecd12903504b, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602121, encodeId=47b2160212112, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-02-16 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=2082941, encodeId=5b5a20829416d, content=<a href='/topic/show?id=b77b9858050' target=_blank style='color:#2F92EE;'>#隔膜肌切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98580, encryptionId=b77b9858050, topicName=隔膜肌切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Dec 19 04:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877120, encodeId=ba7318e7120a4, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 19 13:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268056, encodeId=6c6912680565e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289321, encodeId=d1e4128932170, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290350, encodeId=fecd12903504b, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602121, encodeId=47b2160212112, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-02-16 huiwelcome
  5. [GetPortalCommentsPageByObjectIdResponse(id=2082941, encodeId=5b5a20829416d, content=<a href='/topic/show?id=b77b9858050' target=_blank style='color:#2F92EE;'>#隔膜肌切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98580, encryptionId=b77b9858050, topicName=隔膜肌切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Dec 19 04:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877120, encodeId=ba7318e7120a4, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 19 13:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268056, encodeId=6c6912680565e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289321, encodeId=d1e4128932170, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290350, encodeId=fecd12903504b, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602121, encodeId=47b2160212112, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-02-16 mjldent
  6. [GetPortalCommentsPageByObjectIdResponse(id=2082941, encodeId=5b5a20829416d, content=<a href='/topic/show?id=b77b9858050' target=_blank style='color:#2F92EE;'>#隔膜肌切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98580, encryptionId=b77b9858050, topicName=隔膜肌切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Thu Dec 19 04:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877120, encodeId=ba7318e7120a4, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Thu Dec 19 13:46:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268056, encodeId=6c6912680565e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289321, encodeId=d1e4128932170, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290350, encodeId=fecd12903504b, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602121, encodeId=47b2160212112, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Feb 16 12:46:00 CST 2019, time=2019-02-16, status=1, ipAttribution=)]
    2019-02-16 sunylz

相关资讯

JACC:NT-proBNP指导下的心衰治疗花费更多且无益处

GUIDE-IT临床试验比较了N-末端B型利钠肽(NT-proBNP)指导下的心衰治疗和单纯的内科治疗在高风险心衰患者中的效果,但该研究因无明显作用而被提前终止。本研究的目的旨在评估GUIDE-IT临床试验中的治疗相关生活质量(QOL)和经济产出。本研究对GUIDE-IT临床试验患者中的基线、随机分组后3、6、12和24个月的QOL。在对446名随机分至NT-proBNP指导下心衰治疗组患者和44

JAHA:BMI对急性心力衰竭患者NT-proBNP与发病率和死亡率之间关系的影响!

由此可见,在急性心衰患者中,BMI无法调节NT-proBNP的预后价值。即使在肥胖患者中,NT-proBNP仍然是急性心力衰竭患者长期死亡率一个有用的预后指标。

J Periodontal Res: 血清NT-proBNP水平与牙周炎的关系

N-末端脑利尿钠肽(NT-proBNP)在炎症期间表达并被认为是心血管疾病(CVD)的生物标志物。在过去十年中,有证据表明牙周炎与心血管疾病有关。然而,NT-proBNP在牙周病中的潜在作用鲜为人知。本研究的目的是检查牙周组织中NT-proBNP的水平是否增加,以及是否与牙周炎的严重程度有关。

JAHA:心脏手术前新型心脏生物标志物ST2、半乳凝素-3和NT-ProBNP的预测能力

由此可见,该研究显示冠状动脉旁路移植术患者院内死亡术前预测能力有显著改善,并表明生物标志物可用于识别风险较高的患者。

Int J Cardiol:接受手术心室重建的缺血性心衰患者NT-proBNP水平的纵向变化!

由此可见,在不同时间点的连续NT-proBNP测量(递增或递减)与不良事件风险的调节有关,因此,即使在心脏手术后,NT-proBNP也是监测疾病演变的重要指标。

Blood:不能进行NT-proBNP检查的情况下,也可对AL淀粉样变患者分期了

中心点:采用为阈值BNP>81pg/mL和TnI>0.1ng/mL的AL淀粉样变生物标志物分期系统与以NT-proBNP为基础的系统密切相关。新的以BNP为基础的分期系统可预测AL淀粉样变患者的总体存活率。摘要:免疫球蛋白轻链淀粉样变(AL淀粉样变)是由于轻链错误折叠导致的,形成可溶性的毒性聚合物,在组织器官中沉积导致器官功能障碍。存活的主要决定因素是心脏受累。目前的分期系统采用N末端